Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti‐CD20 monoclonal antibody for the desensitization of candidates for renal transplant

The limited effectiveness of rituximab plus intravenous immunoglobulin (IVIG) in desensitization may be due to incomplete B cell depletion. Obinutuzumab is a type 2 anti‐CD20 antibody that induces increased B cell depletion relative to rituximab and may therefore be more effective for desensitizatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Redfield, Robert R., Jordan, Stanley C., Busque, Stephan, Vincenti, Flavio, Woodle, E. Steve, Desai, Niraj, Reed, Elaine F., Tremblay, Simon, Zachary, Andrea A., Vo, Ashley A., Formica, Richard, Schindler, Thomas, Tran, Ha, Looney, Caroline, Jamois, Candice, Green, Cherie, Morimoto, Alyssa, Rajwanshi, Richa, Schroeder, Aaron, Cascino, Matthew D., Brunetta, Paul, Borie, Dominic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899639/
https://www.ncbi.nlm.nih.gov/pubmed/31257724
http://dx.doi.org/10.1111/ajt.15514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899639/
https://www.ncbi.nlm.nih.gov/pubmed/31257724
http://dx.doi.org/10.1111/ajt.15514

Ejemplares similares